Ocular Therapeutix to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 1-4 in Denver, Colorado and May 11-12 virtually.

“At this year’s Annual Meeting, we are thrilled to be presenting clinical and pre-clinical data from our lead programs as well as from programs that are a part of our early-stage pipeline,” commented Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. “The data being presented continues to highlight the depth of our hydrogel platform and its potential to provide solutions that improve efficacy and reduce the complexity and burden of the current standard of care for a number of diseases in both the front and back-of-the-eye. As we continue to advance our pipeline forward, we remain excited about the progress we have seen to-date and future expansion capabilities into other areas of unmet need.”

Ocular Therapeutix Presentations at ARVO:

OTX-DED (dexamethasone intracanalicular insert) (Dry Eye Disease):

• Title: Efficacy and Safety of OTX-DED Dexamethasone Intracanalicular Insert in Subjects with Dry Eye Disease: A Multicenter, Randomized, Vehicle-Controlled Phase 2 Study
  Session Title: Dry Eye, Clinical
  Session Date/Times: May 2, 2022 from 2:30 PM to 4:30 PM EDT
  Presentation type: Poster session (virtual)
  Presenter: Lisa Nijm

OTX-TKI (axitinib intravitreal implant) (wet AMD and other retinal diseases):

• Title: A Safety and Pharmacokinetic Study of a Novel Hydrogel-based Axitinib Intravitreal Implant (OTX-TKI) in Non-Human Primates
  Session Title: AMD and diabetic retinopathy
  Session Date/Times: May 1, 2022 from 2:15 PM to 4:15 PM EDT
  Presentation type: Poster session
  Presenter: Erica Kahn

• Title: A 6-Month GLP Toxicology Study of a Novel Hydrogel-based, Axitinib Intravitreal Implant (OTX-TKI) in Non-Human Primates
  Session Title: AMD and diabetic retinopathy
  Session Date/Times: May 1, 2022 from 2:15 PM to 4:15 PM EDT
  Presentation type: Poster session
  Presenter: Chintan Patel

OTX-TIC (travoprost intracameral implant) (primary open-angle glaucoma or ocular hypertension):

• Title: Safety and Pharmacodynamic Assessment of Repeated Intracameral Travoprost Implant Administration in Beagle Dogs
  Session Title: Pharmacology/cellular mechanisms